A puzzling medical condition, identified more than 2,000 years ago by Hippocrates, has finally been explained by researchers at the University of Leeds.
"This vaccine represents a very promising therapy for a cancer that comes out of the blue and robs people of something most of us take for granted -- time," said John Sampson, M.D., Ph.D., a neurosurgeon at Duke and lead investigator on this study. "The possibility of doubling expected survival -- with few if any side effects -- would represent a big step and a lot of hope for this group of patients."
Men with a certain type of prostate cancer have been shown to respond to a new chemotherapy drug, Sagopilone, plus prednisone in an international trial led by Oregon Health & Science University Cancer Institute researchers.
New findings from Oregon Health & Science University Cancer Institute show significant numbers of patients nationwide who are not getting the recommended therapy after surgery to remove stomach cancer.
Many long-term survivors of cancer are not receiving the necessary symptom management that they require to help them live with the consequences of their disease, its treatment, or both, according to a leading professor of palliative medicine.
Pinpointing new targets for cancer treatments is as difficult as finding a needle in a haystack, yet a University of Rochester team has discovered an entire novel class of genes they believe will lead to a greater understanding of cancer cell function and the next generation of effective and less harmful therapies for patients.
A new prostate cancer vaccine may give hope to men with metastatic prostate cancer by enabling their immune systems to fight the disease. Researchers from the University of Iowa presented data on the adenovirus/PSA (Ad/PSA) vaccine during the Annual Scientific Meeting of the American Urological Association in Orlando.
